Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia

S Wang-Weigand, M Watissée, T Roth - Sleep medicine, 2011 - Elsevier
OBJECTIVE: Ramelteon is an MT1/MT2 melatonin receptor agonist approved in the US and
Japan for the treatment of sleep-onset insomnia. This study evaluated the effects of …
被引用次数：18 相关文章 所有 3 个版本

Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis

S Wang-Weigand, M McCue, F Ogrinc… - … medical research and …, 2009 - Taylor & Francis
Objective: Ramelteon is an MT1/MT2 melatonin receptor agonist indicated for the treatment
of insomnia characterized by difficulty with sleep onset. In previous clinical studies …
被引用次数：23 相关文章 所有 4 个版本

Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …

L Mini, S Wang-Weigand, J Zhang - Clinical therapeutics, 2008 - Elsevier
Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
被引用次数：41 相关文章 所有 8 个版本
[PDF] academia.edu

The effects of ramelteon in a first-night model of transient insomnia

G Zammit, H Schwartz, T Roth, S Wang-Weigand… - Sleep Medicine, 2009 - Elsevier
OBJECTIVE: To evaluate the efficacy and safety of ramelteon, a highly selective MT1/MT2
melatonin receptor agonist, for the treatment of transient insomnia in adults. METHODS: In a …
被引用次数：67 相关文章 所有 7 个版本

An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia

M Erman, D Seiden, G Zammit, S Sainati, J Zhang - Sleep medicine, 2006 - Elsevier
BACKGROUND AND PURPOSE: To evaluate the efficacy, safety, and dose response of
Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic …
被引用次数：346 相关文章 所有 5 个版本
[HTML] aasm.org

Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia

G Zammit, M Erman, S Wang-Weigand… - Journal of Clinical …, 2007 - jcsm.aasm.org
Objective: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor agonist) in
subjects with chronic primary insomnia. Methods: Randomized, multicenter, double-blind …
被引用次数：255 相关文章 所有 7 个版本
[PDF] academia.edu

Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia

T Roth, D Seiden, S Sainati, S Wang-Weigand, J Zhang… - Sleep medicine, 2006 - Elsevier
BACKGROUND AND PURPOSE: To assess the efficacy and safety of ramelteon, a selective
MT1/MT2 receptor agonist, for chronic insomnia treatment. PATIENTS AND METHODS …
被引用次数：330 相关文章 所有 9 个版本
[PDF] academia.edu

Ramelteon: a review of its use in insomnia

D Simpson, MP Curran - Drugs, 2008 - Springer
Ramelteon (Rozerem™) is the first melatonin receptor agonist to be approved for the
treatment of insomnia; it is not classified as a controlled substance. In patients with chronic …
被引用次数：74 相关文章 所有 11 个版本

Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia

M Uchiyama, M Hamamura, T Kuwano, H Nagata… - Sleep Medicine, 2011 - Elsevier
OBJECTIVE: To evaluate the safety of ramelteon, a highly selective MT1/MT2 melatonin
receptor agonist, during 24weeks' treatment of Japanese patients with chronic insomnia …
被引用次数：44 相关文章 所有 6 个版本

Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis

A Kuriyama, M Honda, Y Hayashino - Sleep medicine, 2014 - Elsevier
Ramelteon is the first selective melatonin receptor agonist and currently is approved in the
United States and Japan for the treatment of insomnia. Our meta-analysis assessed the …
被引用次数：202 相关文章 所有 6 个版本